Capsaicin
Capsaicin is a topical pain reliever derived from chili peppers, used across a range of products to temporarily relieve minor muscle and joint pain, arthritis, strains, and nerve pain (neuropathic pain).
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 139 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Capsaicin: Patient Information Guide
A plain-language walkthrough of Capsaicin — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Capsaicin is used topically (on the skin) for pain relief across a wide range of products — from everyday OTC creams and patches to a prescription-strength patch for nerve pain.
- Temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, strains, sprains, and bruises — supported by multiple OTC creams, ointments, gels, patches, and solutions
- Capsadyn cream: temporary relief of minor aches and pains associated with arthritis, muscle strains, sprains, bruises, related muscle injuries, and simple backache
- Frankie Avalons ZERO PAIN Roll-On Pain Reliever: temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises, and sprains
- Qutenza (prescription patch, applied by a healthcare professional only): neuropathic pain (nerve pain) associated with postherpetic neuralgia (PHN) — lingering pain after shingles — in adults
- Qutenza: neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults
⚙️How it works▾
Capsaicin binds to a receptor on pain-sensing nerve endings in the skin called TRPV1 (transient receptor potential vanilloid 1). When it first activates these receptors, you may feel a burning or warming sensation — that's the nerves firing. With repeated exposure, those nerve endings become desensitized and reduce in number in the treated area, which is how capsaicin quiets pain signals over time. With the prescription-strength Qutenza patch, studies in healthy volunteers confirmed that the density of these nerve fibers in the skin decreases after treatment, and these changes were fully reversible.
💊How it's taken▾
Capsaicin is always applied to the skin — it is never taken by mouth. The right form, frequency, and duration depend on the specific product.
- OTC creams and ointments (such as Capsadyn, Capsaicin 0.025%–0.1% Cream): massage into the affected area up to 3 to 4 times daily; adults 18+ only for most products
- OTC patches (such as Capsaicin Heat Patches, Coralite Capsaicin Heat Patch 2ct): apply to clean, dry skin; do not wear more than 8 hours at a time; use up to 3 to 4 times daily; some brands advise no more than 7 consecutive days of use; for ages 12+
- PainBloc24 topical solution: apply no more than twice a day (every 12 to 24 hours); for adults over 18
- Qutenza (prescription patch): applied only by a healthcare professional in a clinical setting for 30 minutes (DPN of the feet) or 60 minutes (PHN); may be repeated no more frequently than every 3 months
Always wash your hands after applying any capsaicin product, and follow your prescriber's or product label's specific instructions.
🤒Side effects — in detail▾
The most common side effects are at the site where capsaicin is applied, and most are mild and temporary.
- Burning, stinging, or warming sensation — especially with first use
- Skin redness (erythema) at the application site
- Itching at the application site
- Pain at the application site
- Small bumps, swelling, or skin dryness at the application site (more commonly reported with Qutenza)
- Nausea or vomiting (reported with Qutenza)
- Temporary rise in blood pressure (reported with Qutenza)
Stop using immediately and get medical help if you develop severe burning, blistering, or swelling of the skin — rare but serious burns have been reported, particularly with Qutenza when used outside of approved guidelines.
⚠️Warnings & precautions▾
- Keep away from eyes, mouth, and mucous membranes. Capsaicin causes severe irritation if it contacts these areas. If it happens, flush immediately and continuously with cool water and seek medical help.
- Never apply to broken, wounded, sunburned, or irritated skin. This includes wounds, cuts, rashes, or any damaged skin.
- Do not combine with heat sources. Heating pads, hot water bottles, or hot baths close to the time of application can intensify absorption and increase the risk of serious burns.
- Qutenza only — risk of significant application pain and blood pressure changes: Even with a local anesthetic beforehand, patients may experience substantial pain during and after Qutenza application. Blood pressure should be monitored during and after the procedure. Patients with unstable high blood pressure or a recent heart or stroke event may be at higher risk.
- Qutenza only — risk of severe burns: Second- and third-degree burns have been reported, particularly when Qutenza was used outside approved guidelines or at previously traumatized skin sites. Follow dosing instructions exactly.
- Qutenza only — temporary sensory changes: Minor, temporary reductions in the ability to feel heat or sharp sensations have been reported. Patients with pre-existing sensory loss should be assessed before each treatment.
🔀What it interacts with▾
Capsaicin has very few known systemic drug interactions because very little is absorbed into the bloodstream, but there are important local interactions to be aware of.
- Other topical pain-relieving products: Do not use capsaicin at the same time as other topical analgesics on the same area — this increases irritation risk
- Heat sources (heating pads, hot water bottles): Using heat with capsaicin significantly increases the risk of serious skin burns — avoid combining them
- Heat exposure from bathing, exercise, or hot weather: Perspiration and open pores can intensify the burning effect; avoid applying within 1 hour before or after bathing, showering, saunas, or vigorous exercise
- Systemic medications: Drug interaction studies have not been performed, but based on lab studies, capsaicin is not expected to affect the liver enzymes that process most medications, making interactions with systemic drugs unlikely
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Allergy to chili peppers or capsaicin: Do not use if you have had a prior allergic reaction
- Broken or damaged skin: Never apply to wounds, sunburned, chapped, or irritated skin
- Pregnancy: Animal studies with Qutenza showed no evidence of harm to the fetus; systemic absorption from topical use is negligible. Ask a health professional before use if pregnant.
- Breastfeeding: Systemic absorption from topical capsaicin is negligible. For Qutenza specifically, avoid applying to the nipple or areola to prevent direct contact with a nursing infant.
- Children: Qutenza has not been studied in patients under 18. Most OTC creams require a doctor's advice for children under 18; most OTC patches require a doctor's advice for children under 12.
- Older adults: Qutenza was studied extensively in patients 65 and older (75% of PHN trial participants) and was found to be similarly safe and effective — no dose adjustment needed.
- Unstable high blood pressure or recent heart/stroke events: Discuss Qutenza with your doctor before treatment, as it can cause transient blood pressure increases.
- Pre-existing sensory loss or nerve damage: Inform your healthcare professional before each Qutenza treatment so your sensory function can be assessed.
🚑If you take too much▾
There is no clinical experience with capsaicin overdose in humans, and there is no specific antidote. If overdose with Qutenza is suspected, the patch should be gently removed, cleansing gel applied for one minute and wiped off, and the area washed with soap and water. Supportive care and symptom management are recommended. If you believe you or someone else has been overexposed to any capsaicin product, contact Poison Control or seek emergency care.
📡Pharmacodynamics — effects in the body▾
When capsaicin is applied to the skin, it activates TRPV1 receptors on pain-sensing nerve endings, initially causing a burning sensation. With sustained exposure — particularly at prescription strength — the density of those nerve fibers in the skin measurably decreases, reducing pain signaling. Studies with Qutenza in healthy volunteers confirmed reduced epidermal nerve fiber density and minor changes in heat and sharp-sensation detection one week after treatment. Importantly, these changes were fully reversible over time.
🔬Pharmacokinetics — how your body processes it▾
When capsaicin is applied topically at standard doses, only very small, transient amounts are absorbed into the bloodstream — the systemic exposure is considered negligible. Because so little reaches the circulation, capsaicin is not expected to affect the liver enzymes responsible for processing most medications, and interactions with systemic drugs are considered unlikely. Maternal use during pregnancy or breastfeeding is not expected to result in meaningful fetal or infant exposure.
📦How to store it▾
WARNING: FLAMMABLE PRODUCT Store in a cool well-ventilated area away from heat. Keep away from sparks or open flame. Store at 20° to 25°C (68° to 77°F) .
📄 Written from Capsaicin’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Capsaicin — the kind of thing our pharmacy team would talk through with you at the counter.
Why does capsaicin burn when I put it on? Is that normal? ▾
How often should I apply capsaicin cream or use the patch? ▾
What should I do if capsaicin gets into my eyes or mouth? ▾
Can I use a heating pad with my capsaicin patch or cream to help with pain? ▾
Is capsaicin safe to use during pregnancy or while breastfeeding? ▾
When should I stop using capsaicin and call my doctor? ▾
Is Capsaicin available over the counter? ▾
When was Capsaicin first available? ▾
Who makes Capsaicin? ▾
💬 Answers drafted from Capsaicin’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Capsaicin comes
Capsaicin is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Topical cream, ointment or gel
How this form is used
- Capsadyn cream is for temporary relief of minor aches and pains of muscles and joints associated with arthritis, muscle strains, sprains, bruises, related muscle injuries, and simple backache
- Capsaicin 0.025% Cream, Capsaicin 0.035% Cream, Capsaicin 0.05% Cream, and Capsaicin 0.1% Cream are for temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises, and sprains
- Adults 18 and older: apply sparingly to the affected area and massage into the skin until fully absorbed
- May be used up to 3 to 4 times daily; on first use, apply to a small area to test for sensitivity
- Wash hands thoroughly with soap and water after each application to avoid spreading to eyes or mucous membranes
- Children under 18: consult a physician before use
Show 44 more strengths Show fewer strengths
Skin patch
How this form is used
- Capsaicin Heat Patches Back And Large Areas, Capsaicin Hot Patches, and 2-Count HEAT PATCHES are for temporary relief of minor aches and pains of muscles and joints
- Coralite Capsaicin Heat Patch 2ct and Coralite Medicated Heat are for temporary relief of minor muscle and joint pain
- Capsaicin 0.035 Percent patch is for temporary relief of minor aches and pains of muscles and joints
- Adults and children 12 and older: clean and dry the affected area before applying
- Apply the patch to the affected area; do not wear for more than 8 hours at a time
- Do not use more than 3 to 4 times daily; Capsaicin Hot Patches, Capsaicin Heat Patches Back And Large Areas, and 2-Count HEAT PATCHES should not be used for more than 7 consecutive days
- Wash hands with soap and water after applying; children under 12 should not use without consulting a doctor
Show 14 more strengths Show fewer strengths
Topical solution
How this form is used
- Frankie Avalons ZERO PAIN Roll-On Pain Reliever is for temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises, and sprains
- PainBloc24 is for temporary relief of minor aches and pains of muscles and joints
- PainBloc24: adults over 18 — hold the Pain Pen straight down, press the tip repeatedly on the affected area until liquid flows, then dab sparingly; allow to dry
- PainBloc24: repeat as needed every 12 to 24 hours; do not use more than twice a day
- PainBloc24: wash hands with soap and water after each application; if applying to the hand, wait 30 minutes before washing
- Frankie Avalons ZERO PAIN Roll-On Pain Reliever: adults over 18; follow product label directions
Topical spray
📊 Capsaicin across the U.S. market
How Capsaicin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Kit (12) · Powder (7) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Capsaicin is used
A general measure of how commonly Capsaicin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Capsaicin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Capsaicin prescribed? Of the 1,596 medications we measure, Capsaicin ranks #636 by Medicaid prescriptions — more than 60% of them.
Utilization by Capsaicin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
capsaicin 0.25 MG/ML Topical Cream Most dispensed
Summed across the 4 of 38 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198555
capsaicin 1 MG/ML Topical Cream
Summed across the 4 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 646333
capsaicin 0.75 MG/ML Topical Cream
Summed across the 2 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 141868
capsaicin 0.00025 MG/MG Medicated Patch
Summed across the 1 of 51 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1043399
Other Capsaicin products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 3 of 108 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Capsaicin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 14 of 237 listed Capsaicin NDCs with Medicaid activity.
🔍 Compare Capsaicin products
A representative set of FDA-listed product records for Capsaicin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Topical cream, ointment or gel | ||||
| 0.1 g/100 g | Topical | A2A Integrated Pharmaceuticals, LLC | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | A2A Integrated Pharmaceuticals, LLC | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.25 mg/g | Topical | Akorn Consumer Health | OTC MONOGRAPH NOT FINAL | Find on DailyMed ↗ |
| 0.075 g/100 g | Topical | Alaina Healthcare Private Limited | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 g/100 g | Topical | Alexso, Inc | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 g/100 g | Topical | Alexso, Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.035 g/100 g | Topical | Alexso, Inc | OTC MONOGRAPH DRUG | View NDC → |
| 0.075 g/100 g | Topical | Alexso, Inc | OTC MONOGRAPH DRUG | View NDC → |
| 0.075 g/100 g | Topical | Alexso, Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Alexso, Inc | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Alexso, Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/100 g | Topical | Allure Labs | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 g/100 g | Topical | Asclemed USA, Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | AvPAK | OTC MONOGRAPH DRUG | View NDC → |
| 0.75 mg/g | Topical | AvPAK | OTC MONOGRAPH DRUG | View NDC → |
| 0.001 g/g | Topical | AvPAK | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | AvPAK | OTC MONOGRAPH DRUG | View NDC → |
| 1 mg/g | Topical | Better Nature Pty Ltd | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.25 mg/g | Topical | Biosavia Usa, Llc | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Cutaneous | Blaine Labs Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/mL | Topical | Bronson Nutritionals, Llc | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Cardinal Health 110 dba LEADER × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Cardinal Health 110 dba LEADER | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.001 g/g | Topical | Chattem, Inc. × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.001 g/g | Topical | Chattem, Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.25 g/100 g | Topical | Chorda Pharma, Inc | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Cvs Pharmacy | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Cvs Pharmacy | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Danous Land Floow Llc | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | DLC Laboratories, Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | DLC Laboratories, Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.08 g/80 g | Topical | Easment LLC | OTC MONOGRAPH DRUG | View NDC → |
| 0.12 g/120 g | Topical | Easment LLC × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | Fourstar Group Usa, Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/mL | Topical | Frankie Avalon's Venus Ltd. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Guangzhou Tata Biotechnology Co., Ltd. | OTC MONOGRAPH DRUG | View NDC → |
| 0.27 mg/g | Topical | Herbal Motion LLC | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Ideaz, Llc | OTC MONOGRAPH DRUG | View NDC → |
| 0.05 g/100 g | Topical | Innovus Pharmaceuticals, Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.05 g/100 g | Topical | Innovus Pharmaceuticals, Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/100 g | Topical | I Shay Cosmetics Inc | OTC MONOGRAPH DRUG | View NDC → |
| 0.5 mg/g | Topical | Latin Shots, Inc × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.25 mg/mL | Topical | LHP Pharma, Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.0375 g/50 g | Topical | LivCorp Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/100 g | Topical | Lumiera Health Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.35 mg/mL | Topical | Medcore LLC | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 g/100 g | Topical | medsource pharmaceuticals | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.75 mg/g | Topical | Medtech Products Inc × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.25 mg/g | Topical | Nanovita One LLC | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.25 mg/mL | Topical | Nanovita One LLC | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Nationwide Pharmaceutical LLC | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Nationwide Pharmaceutical LLC | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/g | Topical | New World Imports, Inc × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 g/g | Topical | New World Imports, Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Noble OTC LLC × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Noble OTC LLC × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.25 mg/g | Topical | NuCare Pharmaceuticals,Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | NuCare Pharmaceuticals,Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.11 g/100 g | Topical | Nufabrx LLC × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.12 g/100 g | Topical | Nufabrx LLC × 4 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.14 g/100 g | Topical | Nufabrx LLC × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.15 g/100 g | Topical | Nufabrx LLC × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.16 g/100 g | Topical | Nufabrx LLC × 3 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.17 g/100 g | Topical | Nufabrx LLC × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.18 g/100 g | Topical | Nufabrx LLC × 5 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.19 g/100 g | Topical | Nufabrx LLC × 6 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.2 g/100 g | Topical | Nufabrx LLC × 5 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.23 g/100 g | Topical | Nufabrx LLC × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 g/100 g | Topical | Nufabrx LLC × 9 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 g/100 g | Topical | Ol Pharma Tech,llc | OTC MONOGRAPH DRUG | View NDC → |
| 0.35 mg/mL | Topical | Pensivy Sports Products LLC | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.035 g/100 g | Topical | Pharmacure Llc | OTC MONOGRAPH DRUG | View NDC → |
| 0.035 g/100 g | Topical | Preferred Pharmaceuticals Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | Proficient Rx LP | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | Proficient Rx LP | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/100 g | Topical | Proximity Capital Partners LLC dba Asutra × 4 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 g/100 g | Topical | Proximity Capital Partners LLC dba Asutra × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.35 mg/g | Topical | Puretekcorp | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 mg/g | Topical | Puretek Corporation | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | PureTek Corporation | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/mL | Topical | PureTek Corporation | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/mL | Topical | PureTek Corporation × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.5 mg/g | Topical | Puretek Corporation | OTC MONOGRAPH DRUG | View NDC → |
| 1 mg/g | Topical | Puretek Corporation | OTC MONOGRAPH DRUG | View NDC → |
| 0.05 g/100 g | Topical | PureTek Corporation × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.05 g/100 g | Topical | PureTek Corporation × 3 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 3 g/100 g | Topical | Q.A. Laboratories | OTC MONOGRAPH NOT FINAL | View NDC → |
| 2.5 g/100 g | Topical | Qirui Network (shenzhen) Co., Ltd. | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | Rugby Laboratories | OTC MONOGRAPH DRUG | View NDC → |
| 0.25 mg/g | Topical | Rugby Laboratories | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.75 mg/g | Topical | Rugby Laboratories | OTC MONOGRAPH DRUG | View NDC → |
| 0.75 mg/g | Topical | Rugby Laboratories | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Rugby Laboratories | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Rugby Laboratories × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.75 mg/mL | Topical | S.p.o.r.t.s., Llc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/100 g | Topical | Sa3, Llc | OTC MONOGRAPH DRUG | View NDC → |
| 0.025 g/100 g | Topical | Sa3, Llc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 mg/mL | Topical | Sircle Laboratories, LLC | OTC MONOGRAPH NOT FINAL | Find on DailyMed ↗ |
| 0.025 g/100 g | Topical | SOLITEINT Kozmetikum gyarto es forgalmazo, termelo es kereskedelmi Korlatolt Felelossegu Tarsasag | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/100 g | Topical | SOLITEINT Kozmetikum gyarto es forgalmazo termelo es kereskedelmi Korlatolt Felelossegu Tarsasag | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/30 mL | Topical | Taro Pharmaceuticals U.S.A., Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Telebrands Corp | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.18 1 | Topical | Texdel-Based Delivery, Inc. × 3 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.11 g/100 g | Topical | Textile-Based Delivery, Inc. × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.17 g/100 g | Topical | Textile-Based Delivery, Inc. × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.12 1 | Topical | Textile-Based Delivery, Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.13 1 | Topical | Textile-Based Delivery, Inc. | OTC MONOGRAPH NOT FINAL | Find on DailyMed ↗ |
| 0.15 1 | Topical | Textile-Based Delivery, Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.2 1 | Topical | Textile-Based Delivery, Inc. × 4 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.23 1 | Topical | Textile-Based Delivery, Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.14 g/170 g | Topical | Textile-Based Delivery Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.19 g/204.117 g | Topical | Textile-Based Delivery Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.12 1 | Topical | Textile-Based Delivery Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.16 1 | Topical | Textile-Based Delivery Inc × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.19 1 | Topical | Textile-Based Delivery Inc × 3 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.23 1 | Topical | Textile-Based Delivery Inc | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.18 1 | Topical | Textile-Based Delivery Inc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.001 g/g | Topical | Toprail Chp Llc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.001 g/g | Topical | Toprail Chp Llc. | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.025 g/100 g | Topical | Trifecta Pharmaceuticals USA LLC | OTC MONOGRAPH DRUG | View NDC → |
| 0.075 g/100 g | Topical | Trifecta Pharmaceuticals USA LLC | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Trifecta Pharmaceuticals USA LLC | OTC MONOGRAPH DRUG | View NDC → |
| 0.1 g/100 g | Topical | Trifecta Pharmaceuticals USA LLC × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.0002 g/g | Topical | Unifirst First Aid Corporation | OTC MONOGRAPH DRUG | View NDC → |
| 0.075 g/100 g | Topical | ViolaCare, Inc. | OTC MONOGRAPH DRUG | View NDC → |
| 0.3 mg/mL | Topical | Vita Sciences, Llc | OTC MONOGRAPH DRUG | View NDC → |
| 1 mg/g | Topical | Walgreen Company | OTC MONOGRAPH DRUG | View NDC → |
| 1 mg/g | Topical | Walgreen Company | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Walgreen Company × 2 listings | OTC MONOGRAPH DRUG | View NDC → |
| 0.07 g/100 g | Topical | Wellness Products × 2 listings | OTC MONOGRAPH NOT FINAL | View NDC → |
| 0.1 g/100 g | Topical | Xiamen Weisiqi Technology Co., Ltd. | OTC MONOGRAPH DRUG | View NDC → |
| 💊Kits | ||||
| — | — | Averitas Pharma Inc × 8 listings | NDA | View NDC → |
Showing 200 of 316 products — FDA National Drug Code Directory. See every product, package size and price: browse all 316 Capsaicin NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Capsaicin — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Capsaicin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Capsaicin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1992 7 dose forms · 29 strengths
-
Dose form (SCDF) Medicated Patch RxCUI 1792834In current FDA listingsClinical drug / strength (SCD) 0.00025 MG/MGRxCUI 10433990.0003 MG/MGRxCUI 27273930.00035 MG/MGRxCUI 27028590.0005 MG/MGRxCUI 27224140.0015 MG/MGRxCUI 13037340.0025 MG/MGRxCUI 11117390.005 MG/MGRxCUI 27468940.08 MG/MGRxCUI 1039679 -
Dose form (SCDF) Topical Cream RxCUI 377632In current FDA listingsClinical drug / strength (SCD) 0.2 MG/MLRxCUI 5624440.25 MG/MLRxCUI 1985550.3 MG/MLRxCUI 13127470.33 MG/MLRxCUI 18037270.35 MG/MLRxCUI 5773950.5 MG/MLRxCUI 2000830.7 MG/MLRxCUI 5624450.75 MG/MLRxCUI 1418681 MG/MLRxCUI 6463332.5 MG/MLRxCUI 199078 -
Dose form (SCDF) Topical Gel RxCUI 378000In current FDA listings -
Dose form (SCDF) Topical Lotion RxCUI 379381In current FDA listingsClinical drug / strength (SCD) 0.25 MG/MLRxCUI 1985560.35 MG/MLRxCUI 692724 -
Dose form (SCDF) Topical Ointment RxCUI 379104In current FDA listingsClinical drug / strength (SCD) 0.00025 MG/MGRxCUI 3593210.0005 MG/MGRxCUI 19233270.00075 MG/MGRxCUI 359322 -
Dose form (SCDF) Topical Solution RxCUI 371251In current FDA listingsClinical drug / strength (SCD) 0.25 MG/MLRxCUI 2520060.75 MG/MLRxCUI 3589221.5 MG/MLRxCUI 792051 -
Dose form (SCDF) Topical Spray RxCUI 1116917In current FDA listingsClinical drug / strength (SCD) 0.25 MG/MLRxCUI 1116918
Look up RxCUI 1992 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Capsaicin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
…and 16 more on the FDA NDC directory.
RxNorm drug class
Capsaicin belongs to the Capsaicin and similar agents class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 139 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. PureTek Corporation is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.